Elisabetta Bonzano: First-line carboplatin-cyclophosphamid versus paclitaxel for mTNBC

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:

“ First-line carboplatin–cyclophosphamid (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC):

Results from a multicenter, randomized phase lIb trial: The Triple-B study (BOOG 2013-01).

By Marleen Kok Lab.”

Source: Elisabetta Bonzano/X